Overview

Alprostadil Liposomes for Injection for Lower Extremity Arteriosclerosis Obliteran

Status:
Recruiting
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
This is a randomized, positive-control, multicenter, multiple-dose, dose-escalation phase II trial
Phase:
Phase 2
Details
Lead Sponsor:
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Treatments:
Alprostadil